Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM)
- PMID: 3695512
- DOI: 10.1016/0022-4731(87)90387-6
Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM)
Abstract
Tamoxifen, 4-hydroxytamoxifen and desmethyltamoxifen levels were measured in cytosolic and 0.5 M KCl extracted nuclear fractions from a small series of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). Tamoxifen and desmethyltamoxifen were the most abundant metabolites. There was a small increment in the relative abundance of 4-hydroxytamoxifen in the nuclear extract over cytosol relative to both tamoxifen and desmethyltamoxifen. Further, there was a selective retention of tamoxifen relative to desmethyltamoxifen in the nuclear extract relative to the cytosol. It is concluded that all three compounds could potentially contribute to estrogen receptor mediated antiestrogenic effects in this target tissue.
Similar articles
-
Analysis of tamoxifen and 4-hydroxytamoxifen levels in immature rat uterine cytoplasm and KCl-nuclear extracts by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).J Steroid Biochem. 1987 Sep;28(3):289-99. doi: 10.1016/0022-4731(87)91021-1. J Steroid Biochem. 1987. PMID: 3657151
-
Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).J Steroid Biochem. 1987 May;26(5):547-55. doi: 10.1016/0022-4731(87)90006-9. J Steroid Biochem. 1987. PMID: 3586671
-
The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumours.Eur J Cancer Clin Oncol. 1984 Jan;20(1):137-43. doi: 10.1016/0277-5379(84)90045-2. Eur J Cancer Clin Oncol. 1984. PMID: 6420159
-
Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.Br J Cancer. 1987 May;55(5):509-12. doi: 10.1038/bjc.1987.103. Br J Cancer. 1987. PMID: 3606944 Free PMC article.
-
Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.Eur J Cancer Clin Oncol. 1989 Dec;25(12):1769-76. doi: 10.1016/0277-5379(89)90347-7. Eur J Cancer Clin Oncol. 1989. PMID: 2632258
Cited by
-
New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients.Future Sci OA. 2019 Mar 22;5(5):FSO374. doi: 10.2144/fsoa-2018-0113. eCollection 2019 Jun. Future Sci OA. 2019. PMID: 31245038 Free PMC article.
-
Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.Drugs. 1989 Apr;37(4):451-90. doi: 10.2165/00003495-198937040-00004. Drugs. 1989. PMID: 2661195 Review.
-
Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods.Br J Biomed Sci. 2014;71(1):33-9. doi: 10.1080/09674845.2014.11669960. Br J Biomed Sci. 2014. PMID: 24693573 Free PMC article.
-
Combined efficacy of tamoxifen and coenzyme Q10 on the status of lipid peroxidation and antioxidants in DMBA induced breast cancer.Mol Cell Biochem. 2005 May;273(1-2):151-60. doi: 10.1007/s11010-005-0325-3. Mol Cell Biochem. 2005. PMID: 16013450
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous